NUCIEN PHARMA(SH:688189) Xin Lang Cai Jing·2025-10-27 01:58Core Insights - Nanjing Pharmaceutical experienced a 5.23% increase in stock price, reaching 8.86 CNY per share, with a trading volume of 15.72 million CNY and a market capitalization of 2.43 billion CNY [1] Company Overview - Hunan Nanjing Pharmaceutical Co., Ltd. is located in Guangzhou, Guangdong Province, established on December 27, 2006, and listed on March 26, 2020. The company focuses on the research, production, and sales of antiviral and infectious disease prevention drugs, as well as treatments for major diseases like cardiovascular diseases and diabetes. Its main business revenue is derived entirely from chemical drug formulations, accounting for 100% [1] Shareholder Information - Dazhong Fund's Dazhong Jingheng Mixed A (090019) is among the top ten circulating shareholders of Nanjing Pharmaceutical, holding 2.9738 million shares, unchanged from the previous period, representing 1.08% of circulating shares. The estimated floating profit today is approximately 1.3085 million CNY [2] Fund Performance - Dazhong Jingheng Mixed A (090019) was established on June 15, 2012, with a latest scale of 397 million CNY. Year-to-date returns are 39.82%, ranking 1849 out of 8226 in its category. Over the past year, returns are 52.22%, ranking 848 out of 8099, and since inception, returns have reached 369.48% [2] Fund Manager Information - The fund manager of Dazhong Jingheng Mixed A (090019) is Su Bingyi, who has a cumulative tenure of 13 years and 265 days. The total asset scale of the fund is 1.24 billion CNY, with the best fund return during his tenure being 245.86% and the worst being -71.74% [3] Fund Holdings - Dazhong Jingheng Mixed A (090019) has Nanjing Pharmaceutical as its second-largest holding, with 2.9738 million shares, unchanged from the previous period, representing 2.67% of the fund's net value. The estimated floating profit today is approximately 1.3085 million CNY [4]